Immunotherapy of hepatocellular carcinoma.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Hepatology

• Publication date

  2006-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.JHEP.2006.09.004PMID 17046096
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Overexpression of pituitary tumor transforming gene 1 in HCC is associated with angiogenesis and poor prognosis

  2006cited by this paper
• Identification of alpha-fetoprotein-derived peptides recognized by cytotoxic T lymphocytes in HLA-A24+ patients with hepatocellular carcinoma.

  2006cited by this paper
• Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma.

  2006cited by this paper
• Identification of α‐fetoprotein‐derived peptides recognized by cytotoxic T lymphocytes in HLA‐A24+ patients with hepatocellular carcinoma

  2006cited by this paper
• A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma.

  2006cited by this paper
• Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma.

  2006cited by this paper
• Therapie des hepatozellulären Karzinoms

  2006cited by this paper
• A Phase I/II Trial Testing Immunization of Hepatocellular Carcinoma Patients with Dendritic Cells Pulsed with Four α-Fetoprotein Peptides

  2006cited by this paper
• Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma

  2006cited by this paper
• A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides.

  2006cited by this paper
• Expression of cancer-testis antigen (CTA) in tumor tissues and peripheral blood of Chinese patients with hepatocellular carcinoma.

  2006cited by this paper
• Increase of CD4+ CD25+ regulatory T-cells in the liver of patients with hepatocellular carcinoma.

  2006cited by this paper
• [Treatment of hepatocellular carcinoma].

  2006cited by this paper
• Activating anti-CD40 antibodies induce tumour invasion by cytotoxic T-lymphocytes and inhibition of tumour growth in experimental liver cancer.

  2006cited by this paper
• Identification of HLA-A2- or HLA-A24-Restricted CTL Epitopes Possibly Useful for Glypican-3-Specific Immunotherapy of Hepatocellular Carcinoma

  2006cited by this paper
• Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses.

  2006cited by this paper
• Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens.

  2006cited by this paper
• Regulatory T cells, tumour immunity and immunotherapy

  2006cited by this paper
• Patient‐derived dendritic cells transduced with an a‐fetoprotein‐encoding adenovirus and co‐cultured with autologous cytokine‐induced lymphocytes induce a specific and strong immune response against hepatocellular carcinoma cells

  2006cited by this paper
• Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients

  2005cited by this paper
• Compromised lymphocytes infiltrate hepatocellular carcinoma: The role of T‐regulatory cells

  2005cited by this paper
• TSPY is a cancer testis antigen expressed in human hepatocellular carcinoma

  2005cited by this paper
• Administration of dendritic cells in cancer nodules in hepatocellular carcinoma.

  2005cited by this paper
• Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma.

  2005cited by this paper
• Gene- and immunotherapy for hepatocellular carcinoma

  2005cited by this paper
• Analysis of CD4+ T-Cell Responses to a Novel α-Fetoprotein-Derived Epitope in Hepatocellular Carcinoma Patients

  2005cited by this paper
• CD4 T cells in tumor immunity

  2005cited by this paper
• Prevention of Hepatocellular Carcinoma

  2005cited by this paper
• Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.

  2005cited by this paper
• Prevention of hepatocellular carcinoma.

  2005cited by this paper
• Serum Human Telomerase Reverse Transcriptase Messenger RNA as a Novel Tumor Marker for Hepatocellular Carcinoma

  2005cited by this paper
• Expression of cancer/testis (CT) antigens in Chinese hepatocellular carcinoma and its correlation with clinical parameters.

  2005cited by this paper
• EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer.

  2005cited by this paper
• Blockade of B7-H1 with sPD-1 improves immunity against murine hepatocarcinoma.

  2005cited by this paper
• [Expression of NY-ESO-1 and LAGE-1 cancer-testis antigens in hepatocellular carcinoma].

  2005cited by this paper
• Naturally Acquired MAGE-A10- and SSX-2-Specific CD8+ T Cell Responses in Patients with Hepatocellular Carcinoma1

  2005cited by this paper
• Activation of dendritic cells by local ablation of hepatocellular carcinoma.

  2005cited by this paper
• Local/regional and systemic treatments of hepatocellular carcinoma.

  2005cited by this paper
• Specific antihepatocellular carcinoma T cells generated by dendritic cells pulsed with hepatocellular carcinoma cell line HepG2 total RNA.

  2005cited by this paper
• Systemic chemo-immunotherapy for advanced-stage hepatocellular carcinoma.

  2005cited by this paper
• Vaccination of Advanced Hepatocellular Carcinoma Patients with Tumor Lysate-Pulsed Dendritic Cells: A Clinical Trial

  2005cited by this paper
• Immunosuppressive networks in the tumour environment and their therapeutic relevance

  2005cited by this paper
• Dendritic cells pulsed with hsp70-peptide complexes derived from human hepatocellular carcinoma induce specific anti-tumor immune responses.

  2005cited by this paper
• Combination of Conformal Radiotherapy and Intratumoral Injection of Adoptive Dendritic Cell Immunotherapy in Refractory Hepatoma

  2005cited by this paper
• [Expression of MAGE-B genes in hepatocellular carcinoma].

  2004cited by this paper
• Immunotherapeutic strategies for hepatocellular carcinoma.

  2004cited by this paper
• AASLD single‐topic research conference on hepatocellular carcinoma: Conference proceedings

  2004cited by this paper
• Mechanisms and functional significance of tumour-induced dendritic-cell defects

  2004cited by this paper
• Expression of cancer-testis antigens in hepatocellular carcinoma.

  2004cited by this paper
• The Spontaneous CD8+ T-Cell Response to HLA-A2-Restricted NY-ESO-1b Peptide in Hepatocellular Carcinoma Patients

  2004cited by this paper
• Phase II Randomized Trial of Autologous Formalin-Fixed Tumor Vaccine for Postsurgical Recurrence of Hepatocellular Carcinoma

  2004cited by this paper
• Spontaneous Tumor-Specific Humoral and Cellular Immune Responses to NY-ESO-1 in Hepatocellular Carcinoma

  2004cited by this paper
• Chemoembolization for hepatocellular carcinoma.

  2004cited by this paper
• Phase I Clinical Trial of Targeted Therapy Using 131I-Hepama-1 mAb in Patients with Hepatocellular Carcinoma

  2004cited by this paper
• Increased Levels of Interleukin-10 in Serum from Patients with Hepatocellular Carcinoma Correlate with Profound Numerical Deficiencies and Immature Phenotype of Circulating Dendritic Cell Subsets

  2004cited by this paper
• CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

  2004cited by this paper
• Ex vivo characterization of tumor-derived melanoma antigen encoding gene-specific CD8+cells in patients with hepatocellular carcinoma.

  2004cited by this paper
• Telomerase and c-myc expression in hepatocellular carcinomas.

  2004cited by this paper
• Expression of co-stimulator 4-1BB molecule in hepatocellular carcinoma and adjacent non-tumor liver tissue, and its possible role in tumor immunity.

  2004cited by this paper
• Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant.

  2004cited by this paper
• IL-6 Regulates In Vivo Dendritic Cell Differentiation through STAT3 Activation1

  2004cited by this paper
• Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma.

  2004cited by this paper
• Focus on hepatocellular carcinoma.

  2004cited by this paper
• Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors.

  2004cited by this paper
• α-Fetoprotein Impairs APC Function and Induces Their Apoptosis1

  2004cited by this paper
• Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma.

  2003cited by this paper
• Adoptive-cell-transfer therapy for the treatment of patients with cancer

  2003cited by this paper
• Dendritic cell-based vaccination in solid cancer.

  2003cited by this paper
• Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatocellular carcinoma-A phase II trial

  2003cited by this paper
• Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma.

  2003cited by this paper
• The biology of VEGF and its receptors

  2003cited by this paper
• Potentiation of therapeutic immune responses against malignancies with monoclonal antibodies.

  2003cited by this paper
• A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer

  2003cited by this paper
• T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer.

  2003cited by this paper
• Altered maturation of peripheral blood dendritic cells in patients with breast cancer

  2003cited by this paper
• [Expression of tumor-specific cancer/testis antigens in hepatocellular carcinoma].

  2003cited by this paper
• CD40 in hepatocellular carcinoma: relevant or not?

  2003cited by this paper
• Identification of the antigens predominantly reacted with serum from patients with hepatocellular carcinoma

  2003cited by this paper
• Heterogeneous expression and regulation of CD40 in human hepatocellular carcinoma

  2003cited by this paper
• Systemic Combined Chemotherapy with Low Dose of 5-Fluorouracil, Cisplatin, and Interferon-α for Advanced Hepatocellular Carcinoma: A Pilot Study

  2003cited by this paper
• Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses.

  2003cited by this paper
• CD4+CD25+ suppressor T cells: more questions than answers

  2002cited by this paper
• Prospective Pilot Study of Recombinant Granulocyte-Macrophage Colony-Stimulating Factor and Interferon-&ggr; in Patients With Inoperable Hepatocellular Carcinoma

  2002cited by this paper
• Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck.

  2002cited by this paper
• Expression of cancer-testis genes in human hepatocellular carcinomas.

  2002cited by this paper
• Treatment of non‐resectable hepatocellular carcinoma with autologous tumor‐pulsed dendritic cells

  2002cited by this paper
• Ultra-Low-Dose Interleukin-2 in Unresectable Hepatocellular Carcinoma

  2002cited by this paper
• Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens

  2002cited by this paper
• CD4(+) and CD8(+) anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity.

  2002cited by this paper
• Tumor‐specific shared antigenic peptides recognized by human T cells

  2002cited by this paper
• Cancer/testis antigens: an expanding family of targets for cancer immunotherapy

  2002cited by this paper
• Identification of tumour-associated t-cell epitopes for vaccine development

  2002cited by this paper
• Large Scale Identification of Human Hepatocellular Carcinoma-Associated Antigens by Autoantibodies1

  2002cited by this paper
• Transforming growth factor-beta1 triggers hepatocellular carcinoma invasiveness via alpha3beta1 integrin.

  2002cited by this paper
• Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6.

  2002cited by this paper
• Cirrhotic Patients With or Without Hepatocellular Carcinoma Harbour AFP-Specific T-Lymphocytes That Can Be Activated in vitro by Human Alpha-Fetoprotein

  2002cited by this paper
• Effects of Long-Term Postoperative Interferon- Therapy on Intrahepatic Recurrence after Resection of Hepatitis C VirusRelated Hepatocellular Carcinoma

  2001cited by this paper
• Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial.

  2001cited by this paper
• Expressions of cancer-testis antigens in human hepatocellular carcinomas.

  2001cited by this paper
• T Cell Responses to HLA-A*0201-Restricted Peptides Derived from Human α Fetoprotein1

  2001cited by this paper

• Immune Checkpoint FGL1 Expression of Circulating Tumor Cells Is Associated With Poor Survival in Curatively Resected Hepatocellular Carcinoma

  2022cites this paper
• Interventional radiology meets immuno-oncology for hepatocellular carcinoma.

  2022cites this paper
• Consensus of Minimally Invasive and Multidisciplinary Comprehensive Treatment for Hepatocellular Carcinoma – 2020 Guangzhou Recommendations

  2021cites this paper
• Genomic DNA methylation profiling indicates immune response following thermal ablation treatment for HBV-associated hepatocellular carcinoma

  2020cites this paper
• Trends in the treatment of advanced hepatocellular carcinoma: immune checkpoint blockade immunotherapy and related combination therapies.

  2019cites this paper
• Identification of key genes and pathways associated with different immune statuses of hepatitis B virus infection

  2019cites this paper
• Integrating Osteopathic Philosophy in Cancer Care

  2019cites this paper
• Therapeutic advances for patients with intermediate hepatocellular carcinoma

  2019cites this paper
• Recent Advances and Future Directions in Immunotherapeutics for Hepatocellular Carcinoma

  2019cites this paper
• Preparation and preliminary in vivo evaluation of 166 Ho-labeled microspheres for possible use in radioembolic therapy of liver cancer.

  2018cites this paper
• Biological effects of radiation on cancer cells

  2018cites this paper
• A four‐gene‐based prognostic model predicts overall survival in patients with hepatocellular carcinoma

  2018cites this paper
• Immune Regulation in HCC and the Prospect of Immunotherapy

  2018cites this paper
• Plasmodium parasite as an effective hepatocellular carcinoma antigen glypican-3 delivery vector

  2017cites this paper
• A hepatic stem cell vaccine is superior to an embryonic stem cell vaccine in the prophylaxis and treatment of murine hepatocarcinoma.

  2017cites this paper
• Development of Semiautomated Module for Preparation of 131I Labeled Lipiodol for Liver Cancer Therapy

  2017cites this paper
• Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer

  2017cites this paper
• Tumor-infiltrating B cells producing antitumor active immunoglobulins in resected HCC prolong patient survival

  2017cites this paper
• Cellular and molecular targets for the immunotherapy of hepatocellular carcinoma

  2017cites this paper
• Targets for immunotherapy of liver cancer.

  2017cites this paper
• Cellular Immune Responses for Squamous Cell Carcinoma Antigen Recognized by T Cells 3 in Patients with Hepatocellular Carcinoma

  2017cites this paper
• Herbal Medicine Offered as an Initiative Therapeutic Option for the Management of Hepatocellular Carcinoma

  2016cites this paper
• Perspectives of immunotherapy in hepatocellular carcinoma (HCC)

  2016cites this paper
• A Fixed Human Umbilical Vein Endothelial Cell Vaccine With 2 Tandem Repeats of Microbial HSP70 Peptide Epitope 407-426 As Adjuvant for Therapy of Hepatoma in Mice

  2015cites this paper
• Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches

  2015cites this paper
• The Immune System in Hepatocellular Carcinoma and Potential New Immunotherapeutic Strategies

  2015cites this paper
• Tumor‐infiltrating, interleukin‐33–producing effector‐memory CD8+ T cells in resected hepatocellular carcinoma prolong patient survival

  2015cites this paper
• Potentiality of immunotherapy against hepatocellular carcinoma.

  2015cites this paper
• Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes

  2014cites this paper
• Sorting Out Pandora’s Box: Discerning the Dynamic Roles of Liver Microenvironment in Oncolytic Virus Therapy for Hepatocellular Carcinoma

  2014cites this paper
• Effects of the Treg/Th17 cell balance and their associated cytokines in patients with hepatitis B infection

  2014cites this paper
• Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma

  2014cites this paper
• Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican-3-derived peptide

  2013cites this paper
• Hepatocellular Carcinoma from an Immunologic Perspective

  2013cites this paper
• Identification of an H2-Kb or H2-Db restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide

  2013cites this paper
• ABORDAGEM TERAPÊUTICA DO CARCINOMA HEPATOCELULAR

  2013cites this paper
• Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination

  2013cites this paper
• Human CCR4+CCR6+Th17 Cells Suppress Autologous CD8+ T Cell Responses

  2012cites this paper
• EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.

  2012cites this paper
• Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival

  2012cites this paper
• Cellular Immune Suppressor Mechanisms in Patients with Hepatocellular Carcinoma

  2012cites this paper
• Translational medicine in hepatocellular carcinoma

  2012cites this paper
• Expression of chondroitin‐glucuronate C5‐epimerase and cellular immune responses in patients with hepatocellular carcinoma

  2012cites this paper
• EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.

  2012cites this paper
• Immunotherapy of hepatocellular carcinoma

  2012cites this paper
• Immunotherapy of hepatocellular carcinoma

  2012cites this paper
• EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver ⇑ , European Organisation for Research and Treatment of Cancer

  2012cites this paper
• Immunotherapy of hepatocellular carcinoma: is there a place for regulatory T-lymphocyte depletion?

  2011cites this paper
• A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma

  2010cites this paper
• Dendritic cells-mediated CTLs targeting hepatocellular carcinoma stem cells

  2010cites this paper
• Gene therapy for HCV/HBV-induced hepatocellular carcinoma.

  2010cites this paper
• Low-dose Cyclophosphamide Treatment Impairs Regulatory T Cells and Unmasks AFP-specific CD4+ T-cell Responses in Patients With Advanced HCC

  2010cites this paper
• Preparation of 177Lu-Labeled Oxine in Lipiodol as a Possible Agent for Therapy of Hepatocellular Carcinoma: A Preliminary Animal Study

  2010cites this paper
• 215 A PHASE II OPEN LABEL TRIAL EVALUATING SAFETY AND EFFICACY OF A TELOMERASE PEPTIDE VACCINATION IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA

  2010cites this paper
• Frequent expression of the novel cancer testis antigen MAGE‐C2/CT‐10 in hepatocellular carcinoma

  2009cites this paper
• DNAX accessory molecule‐1 (CD226) promotes human hepatocellular carcinoma cell lysis by Vγ9Vδ2 T cells

  2009cites this paper
• Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma.

  2009cites this paper
• A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells.

  2008cites this paper
• Inhibition of CD44 expression in hepatocellular carcinoma cells enhances apoptosis, chemosensitivity, and reduces tumorigenesis and invasion

  2008cites this paper
• Immunotherapy of HCC.

  2008cites this paper
• Targeting chemokines as a therapeutic option for hepatocellular carcinoma: A reality or just a fantasy?

  2007cites this paper
• Regulatory T lymphocytes: pivotal components of the host antitumor response.

  2007cites this paper